38.85
0.15 (0.39%)
| Previous Close | 38.70 |
| Open | 38.94 |
| Volume | 188,564 |
| Avg. Volume (3M) | 539,177 |
| Market Cap | 1,853,424,640 |
| Price / Earnings (Forward) | 59.52 |
| Price / Sales | 5.69 |
| Price / Book | 8.51 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -32.51% |
| Operating Margin (TTM) | -14.03% |
| Diluted EPS (TTM) | -2.08 |
| Quarterly Revenue Growth (YOY) | 89.40% |
| Total Debt/Equity (MRQ) | 136.91% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -1.23 M |
| Levered Free Cash Flow (TTM) | -3.10 M |
| Return on Assets (TTM) | -9.10% |
| Return on Equity (TTM) | -39.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Mirum Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.24% |
| % Held by Institutions | 115.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 68.00 (Citigroup, 75.03%) | Buy |
| Median | 58.00 (49.29%) | |
| Low | 49.00 (Leerink Partners, 26.13%) | Buy |
| Average | 58.25 (49.94%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 42.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 13 Nov 2024 | 50.00 (28.70%) | Buy | 43.92 |
| Citigroup | 13 Nov 2024 | 68.00 (75.03%) | Buy | 43.92 |
| HC Wainwright & Co. | 13 Nov 2024 | 66.00 (69.88%) | Buy | 43.92 |
| 11 Oct 2024 | 66.00 (69.88%) | Buy | 40.11 | |
| Leerink Partners | 17 Oct 2024 | 49.00 (26.13%) | Buy | 39.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |